ArticleReports (MDPI)2025

Sustained Complete Response to Trastuzumab Deruxtecan Beyond Treatment Discontinuation in a Heavily Pretreated HER2-Positive Breast Cancer Patient with Skin Metastases: A Case Report.

Maria Puleo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.